ImQuest BioSciences offers a panel of in vitro mitochondrial toxicity assays to evaluate the off-target effects of pharmaceutical products on mitochondrial function. Implicated in a wide variety of toxicological outcomes, adverse effects on the liver, cardiac and kidney tissues can result from dysregulation of mitochondrial function. These assays can be utilized to better predict the off-target effect of novel chemical or biological entities. Test articles can also be tested in a wide variety of primary cell models in addition to thee biochemical and cell based mitochondrial toxicity assays. Various molecular and protein based endpoints can be quantified readily by qPCR and molecular methods, as well as protein markers of mitochondrial function by Luminex endpoints.

Inquire to learn more about our in vitro toxicity services.

Mitochondrial Toxicity Assays

• Mitochondrial mitogenesis and protein production
• Mitochondrial respiration and function
• Mitochondrial membrane integrity assays
• Quantification and evaluation of mitochondrial MT-ND1 gene expression (evaluation of other gene products available)
• Effect of Glucose/Galactose medias on mitochondrial function
• DNA polymerase assays (alpha, beta and gamma polymerases)
• Human mitochondrial RNA polymerase biochemical assays
• Human oxidative phosphorylation magnetic bead panels (Luminex)
• Mechanism of viral or test article induced cell death (e.g., necrosis, apoptosis, pyroptosis)

• Long term evaluations in differentiated HepRG cell based assays
• Primary cell and iPSC based cell viability and functional assays (Liver, cardiac, kidney, other cell types available on request)